Waypoint Bio

Waypoint Bio is a biotechnology company that pioneers novel cell therapies for solid tumors by leveraging its proprietary spatial ensemble screening technology and in-lab cycling methods. Since its establishment in 2024, the company has raised $14.5 million from leading biotech and tech investors and formed a scientific advisory board composed of drug development and cancer experts. While currently focused on designing innovative cell therapies for solid cancer tumors, its technology holds potential applications across broader drug discovery areas, including Treg therapies for autoimmune diseases.